Tag: allergy
Allero Therapeutics Receives EIC Horizon Grant to Advance Treatment of Celiac Disease
– Specific OroMucosal ImmunoTherapy (SOMIT) for celiac disease patients supported with EUR 2.5mn funding
Allero Therapeutics BV, a Dutch oromucosal immunotherapy company, today announced that the Company has received a EUR 2.5 million EIC Horizon Grant provided by the European Commission to advance novel treatments for celiac disease patients. The program is based on Allero´s proprietary SOMIT (Specific OroMucosal ImmunoTherapy) platform technology for the treatment of antigen-driven immune disorders.
Company News: Anergis Presents Sustained Efficacy Data from its AllerT Phase IIb Trial at the AAAAI Annual Meeting
– Contiguous Overlapping Peptide allergy immunotherapeutic AllerT confirms sustained efficacy in the second year following treatment
Anergis, a company developing novel and proprietary ultra-fast allergy immunotherapeutics, presented detailed data from the Phase IIb trial of its birch pollen allergy immunotherapeutic AllerT in two separate scientific posters at the AAAAI (American Academy of Allergy, Asthma and Immunology) Annual Meeting in Houston, Texas. The findings were presented on February 22, 2015. Abstracts can be found at www.anergis.ch. AllerT is Anergis´ most advanced long-peptide immunotherapeutic and based on the company´s proprietary Contiguous Overlapping Peptide (COP) platform.
In 2013, the clinical efficacy of AllerT was demonstrated in a field-based, randomized, placebo-controlled, double-blind trial in 239 patients with birch pollen allergy, who received either AllerT (at 50μg or 100μg doses) or a placebo during a 2-month immunotherapy regimen. All main efficacy and safety endpoints were met in this study.
In 2014, the sustained efficacy of AllerT was assessed in the same group of patients during a second follow-up season without additional treatment. In both years, efficacy was evaluated using combined Rhinoconjunctivitis Symptom and Medication Scores (RSMS) as the primary endpoint as well as quality of life (Mini RQLQ) and Night-time Nasal Symptom Score (NNSS) as the main secondary endpoints. The study also measured the levels of allergen-specific immunoglobulins (Bet v 1 specific IgG4) in patients.
The data collected during the second post-treatment season (N=196 patients) proved the sustained efficacy of AllerT, as demonstrated by improvements in the primary endpoint, RSMS, and in the main secondary endpoints, Mini RQLQ and NNSS. The trial also confirmed that AllerT had induced a persistent elevation of anti-Bet v 1 IgG4 antibodies, i.e. measured after one year without treatment.
Company News: Anergis Obtains Core Technology Patent in Japan
– Patent covers Contiguous Overlapping Peptide technology for the development of ultra-fast allergy vaccines –
Anergis, a company focusing on proprietary allergy vaccines, today announced it was granted a Japanese patent on its key technology from the Japanese Patent Office. The patent #5389326 broadly covers the Contiguous Overlapping Peptide (COP) technology which is used by Anergis to define and select new products for the ultra-fast treatment of multiple allergies.
“We have already been granted patents protecting our COP technology in the U.S. and Australia,” said Christophe Reymond, CSO of Anergis. “COPs are pharmaceutical quality products that provide the complete allergen sequence covering all T cell epitopes, but do not elicit allergic hypersensitivity. Therefore, COPs can be administered safely at high doses to induce tolerance to the allergen after a few injections only.”
He added that Anergis has already demonstrated in Phase I/IIa and IIb trials that just five injections of its lead COP allergy vaccine AllerT over a period of two months were sufficient to achieve long-lasting immunological effects as well as seasonal symptom reductions in allergic patients, similar to conventional allergy immunotherapy.
“Obtaining patent protection in Japan is an important milestone for Anergis because the Japanese population suffers from numerous allergies, particularly to house dust mites and to Japanese cedar,” said Vincent Charlon, CEO of Anergis.
Anergis’ COP technology can be applied to a broad spectrum of allergy indications. At present, Anergis is developing AllerT for the treatment of birch pollen allergy, AllerR for ragweed pollen allergies and AllerDM for dust mite allergies.